Cover Image
市場調查報告書

Amplyx Pharmaceuticals, Inc. - 產品平台分析

Amplyx Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293944
出版日期 內容資訊 英文 21 Pages
訂單完成後即時交付
價格
Back to Top
Amplyx Pharmaceuticals, Inc. - 產品平台分析 Amplyx Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年03月26日 內容資訊: 英文 21 Pages
簡介

Amplyx Pharmaceuticals, Inc.正在開發、供給治療腫瘤及感染疾病用小分子藥劑。該公司產品之HIV蛋白分解酵素抑制劑和癌症治療藥均是低毒性。

本報告提供Amplyx Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Amplyx Pharmaceuticals, Inc.的基本資料

Amplyx Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Amplyx Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Amplyx Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Amplyx Pharmaceuticals, Inc.:開發中產品概況

  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Amplyx Pharmaceuticals, Inc.:藥物簡介

  • FK506 Analogues
  • Small Molecule to Inhibit Tubulin for Breast Cancer
  • Small Molecules to Inhibit HIV Protease for HIV/AIDS
  • Small Molecules to Inhibit Pkh2 for Cryptococcal Meningitis

Amplyx Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Amplyx Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06902CDB

Summary

Global Markets Direct's, 'Amplyx Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Amplyx Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amplyx Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Amplyx Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Amplyx Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Amplyx Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Amplyx Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Amplyx Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Amplyx Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Amplyx Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amplyx Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Amplyx Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Amplyx Pharmaceuticals, Inc. Snapshot
    • Amplyx Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Amplyx Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Amplyx Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Amplyx Pharmaceuticals, Inc. - Pipeline Products Glance
    • Amplyx Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Amplyx Pharmaceuticals, Inc. - Drug Profiles
    • FK506 Analogues
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Tubulin for Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit PBP for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit HIV Protease for HIV/AIDS
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Pkh2 for Cryptococcal Meningitis
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Amplyx Pharmaceuticals, Inc. - Pipeline Analysis
    • Amplyx Pharmaceuticals, Inc. - Pipeline Products by Target
    • Amplyx Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Amplyx Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Amplyx Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Amplyx Pharmaceuticals, Inc., Key Information
  • Amplyx Pharmaceuticals, Inc., Key Facts
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Amplyx Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Amplyx Pharmaceuticals, Inc. - Preclinical, 2015
  • Amplyx Pharmaceuticals, Inc. - Discovery, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Amplyx Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Amplyx Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Amplyx Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top